BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-05
212 industry Phase 2/3 trial readout(s) and 22 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-05 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT03883087 A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation | Chronic Myeloid Leukemia, Chronic Phase | unknown | 41 |
| 2024-05 est. | P2 | RemeGen Co., Ltd. | NCT04782128 Evaluation of RC28-E Injection in Diabetic Retinopathy | Diabetic Retinopathy | unknown | 120 |
| 2024-05 est. | P2 | Impact Therapeutics, Inc. IBO | NCT04822961 Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment | mCRPC | unknown | 285 |
| 2024-05 est. | P2 | Kartos Therapeutics, Inc. | NCT04878003 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV-MF); Post-Essential Throm | unknown | 52 |
| 2024-05 est. | P2 | eXIthera Pharmaceuticals | NCT05040776 COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients | Thrombopenia; Covid19 | withdrawn | |
| 2024-05 est. | P3 | Bio Genuine (Shanghai) Biotech Co., Ltd. | NCT05620355 Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | Uterine Fibroids; Heavy Menstrual Bleeding | unknown | 312 |
| 2024-05 est. | P2 | Nova Mentis Life Science Corp NVMI | NCT05832255 An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome | Fragile X Syndrome; Behavior; Cognitive Dysfunction | suspended | 10 |
| 2024-05 est. | P3 | Pharmbio Korea Co., Ltd. | NCT05923918 A Study to Evaluate Safety and Efficacy of PBK_M2101 | Intestinal Disease; Colonic Diseases; Gastrointestinal Disease; Digestive System Disease | unknown | 246 |
| 2024-05 est. | P3 | AJU Pharm Co., Ltd. | NCT06291194 Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients | Dry Eye Syndromes | unknown | 396 |
| 2024-05-01 | P3 | Janssen Research & Development, LLC | NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | completed | 390 |
| 2024-05-01 | P3 | Janssen Research & Development, LLC | NCT04181827 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Da | Multiple Myeloma | active not recruiting | 419 |
| 2024-05-01 | P2 | Boehringer Ingelheim | NCT05238675 A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis | Bronchiectasis | completed | 322 |
| 2024-05-01 | P2 | Hoffmann-La Roche | NCT05419388 A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | Melanoma | completed | 93 |
| 2024-05-01 | P2/P3 | Lavior Pharma Inc. | NCT05607979 Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds | Diabetic Foot Ulcer | completed | 75 |
| 2024-05-01 | P2 | Vogenx, Inc. VOGX | NCT05721729 Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions | Postbariatric Hypoglycemia | completed | 15 |
| 2024-05-01 est. | P2 | Kunming Pharmaceuticals, Inc. | NCT05745311 Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | unknown | 240 |
| 2024-05-01 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06223308 A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor; Cervical Cancer | unknown | 54 |
| 2024-05-02 | P2 | GlaxoSmithKline | NCT03739710 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | Neoplasms | completed | 175 |
| 2024-05-02 | P3 | Sydnexis, Inc. | NCT03918915 The Safety and Efficacy of SYD-101 in Children With Myopia | Nearsightedness; Near Sightedness; Near-sightedness | completed | 852 |
| 2024-05-02 | P2 | Akero Therapeutics, Inc | NCT04767529 A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | completed | 128 |
| 2024-05-02 | P2 | Boehringer Ingelheim | NCT05161481 A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the | Hypertension, Portal | terminated | 80 |
| 2024-05-02 | P2 | Sage Therapeutics | NCT05173012 Study to Evaluate SAGE-324 in Participants With Essential Tremor | Essential Tremor | completed | 146 |
| 2024-05-02 | P2 | AstraZeneca AZN | NCT05432167 A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease | Uncontrolled Hypertension; Chronic Kidney Diseases | completed | 195 |
| 2024-05-02 | P3 | Oculis OCS | NCT06128369 A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Followin | Inflammation Eye Pain; Postoperative Cataract | terminated | 117 |
| 2024-05-02 | P2 | GlaxoSmithKline | NCT06926673 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 | Neoplasms | completed | 62 |
| 2024-05-03 | P3 | Agios Pharmaceuticals, Inc. AGIO | NCT05144256 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed | Pediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia | active not recruiting | 49 |
| 2024-05-03 | P3 | Eli Lilly and Company LLY | NCT05372419 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of | Atopic Dermatitis | completed | 90 |
| 2024-05-03 | P2 | Cocrystal Pharma, Inc. COCP | NCT06160531 Influenza Viral Challenge Study of CC-42344 in Healthy Participants | Influenza A | completed | 78 |
| 2024-05-05 | P3 | Shanghai Bao Pharmaceuticals Co., Ltd. | NCT06604546 Hyaluronidase Assisted Subcutaneous Infusion | Healthy | completed | 45 |
| 2024-05-06 | P1/P2 | Hoffmann-La Roche | NCT04029688 A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in T | Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Neuroblastoma; Solid Tumors | terminated | 38 |
| 2024-05-06 | P3 | AO GENERIUM | NCT05601999 Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction | ST Elevation Myocardial Infarction | completed | 244 |
| 2024-05-07 | P3 | Janssen Research & Development, LLC | NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants | Multiple Myeloma | completed | 395 |
| 2024-05-07 | P1/P2 | MedPacto, Inc. | NCT03724851 Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | Metastatic Colorectal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | completed | 120 |
| 2024-05-07 | P2/P3 | Merck Sharp & Dohme LLC MRK | NCT03969901 Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infectio | Suspected or Documented Gram-negative Bacterial Infection | completed | 115 |
| 2024-05-07 | P3 | Shanghai Henlius Biotech | NCT04063163 A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | Extensive Stage Small Cell Lung Cancer | completed | 585 |
| 2024-05-07 | P3 | POLYSAN Scientific & Technological Pharmaceutical Company | NCT04631484 International Trial of Efficacy of Cytoflavin in Head Trauma | Head Trauma,Closed | completed | 166 |
| 2024-05-07 | P1/P2 | Claris Biotherapeutics, Inc. | NCT04909450 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects | Neurotrophic Keratitis | completed | 131 |
| 2024-05-07 | P3 | Shanghai Henlius Biotech | NCT05003245 Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD | Age Related Macular Degeneration | completed | 407 |
| 2024-05-07 | P3 | Alvotech Swiss AG ALVO | NCT05395091 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND | Osteoporosis, Postmenopausal | completed | 532 |
| 2024-05-07 | P3 | Eli Lilly and Company LLY | NCT05463744 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy | Type 1 Diabetes; Diabetes | completed | 692 |
| 2024-05-07 | P2 | SK Plasma Co., Ltd. | NCT05666453 A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation | Liver Transplantation | terminated | 59 |
| 2024-05-07 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT05803642 A Study of Olanzapine in Patients With Acute Agitation | Acute Agitation | unknown | 318 |
| 2024-05-07 | P1/P2 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT06010953 SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment | Male; Hemophilia A With Inhibitor; Hemophilia B With Inhibitor; Hemophilia | completed | 24 |
| 2024-05-08 | P3 | Alnylam Pharmaceuticals ALNY | NCT04153149 HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | active not recruiting | 655 |
| 2024-05-08 | P2 | Oblato, Inc. | NCT04388475 Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | Recurrent Malignant Glioma; Brain Glioblastoma | completed | 57 |
| 2024-05-08 | P1/P2 | TyrNovo Ltd. | NCT04474470 A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | Solid Tumor, Adult; Squamous Cell Carcinoma of Head and Neck; Colorectal Adenocarcinoma; Metastatic | completed | 52 |
| 2024-05-08 | P2 | Astellas Pharma Inc | NCT04641962 A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy | Primary Mitochondrial Myopathy | terminated | 34 |
| 2024-05-08 | P2 | BioMed Valley Discoveries, Inc | NCT05221320 Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Tumor, Solid; Gastrointestinal Cancer | terminated | 47 |
| 2024-05-08 | P2 | Inventiva Pharma IVA | NCT05232071 Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in pa | NASH - Nonalcoholic Steatohepatitis; Diabetes Mellitus, Type 2 | completed | 39 |
| 2024-05-09 | P1/P2 | Celgene | NCT02773030 A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | Multiple Myeloma | active not recruiting | 466 |
| 2024-05-09 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04569032 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Peripheral T-cell Lymphoma | completed | 82 |
| 2024-05-09 | P3 | Stratatech, a Mallinckrodt Company | NCT05517902 StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects | Skin Wound; Burns; Trauma-related Wound | completed | 1 |
| 2024-05-10 | P3 | Hoffmann-La Roche | NCT03969212 Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households | Influenza | completed | 4138 |
| 2024-05-10 | P2 | Cellaion SA | NCT04229901 Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) | Acute on Chronic Liver Failure | terminated | 133 |
| 2024-05-10 | P3 | Daiichi Sankyo | NCT04656652 Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPI | Non-small Cell Lung Cancer | active not recruiting | 605 |
| 2024-05-10 | P2 | Akeso | NCT04870177 Study of AK112 in the Treatment of Advanced Gynecological Tumors | Gynecologic Cancer; Cancer Metastatic; Ovarian Neoplasms; Cervical Neoplasm; Endometrial Neoplasms | completed | 53 |
| 2024-05-10 | P3 | Asklepion Pharmaceuticals, LLC | NCT05253209 A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in | Ventricular Septal Defect; Atrioventricular Septal Defect; Primum Atrial Septal Defect | terminated | 64 |
| 2024-05-10 | P3 | Serum Institute of India Pvt. Ltd. | NCT05421611 A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL | Yellow Fever | completed | 1824 |
| 2024-05-10 | P2 | GeNeuro SA | NCT05497089 Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome | Post-COVID-19 Syndrome | completed | 203 |
| 2024-05-10 | P2 | Biotheus Inc. | NCT05844150 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | SCLC | active not recruiting | 50 |
| 2024-05-10 | P3 | ModernaTX, Inc. | NCT06354998 A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | SARS-CoV-2 | completed | 217 |
| 2024-05-11 | P3 | Celgene | NCT01996865 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. | Lymphoma, Non-Hodgkin | completed | 503 |
| 2024-05-11 | P2 | Jiangsu vcare pharmaceutical technology co., LTD | NCT05814939 Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | Active Ankylosing Spondylitis | completed | 180 |
| 2024-05-11 | P3 | Mimetogen Pharmaceuticals USA, Inc. | NCT05848128 Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye | Dry Eye Syndromes; Dry Eye Disease; Kerato Conjunctivitis Sicca | completed | 642 |
| 2024-05-13 | P2 | TikoMed AB | NCT03867851 Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation | Diabetes Mellitus, Type 1 | terminated | 7 |
| 2024-05-13 | P2 | Neuren Pharmaceuticals Limited | NCT05011851 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Angelman Syndrome | completed | 17 |
| 2024-05-13 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05403749 A Study of Longer Interval of IVT IBI302 in Subjects With nAMD | Neovascular Age-related Macular Degeneration | completed | 132 |
| 2024-05-13 | P2 | Clarity Pharmaceuticals Ltd | NCT05407311 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) | Biochemical Recurrence of Malignant Neoplasm of Prostate | completed | 53 |
| 2024-05-13 | P3 | Chong Kun Dang Pharmaceutical | NCT05931224 Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy | Essential Hypertension | completed | 346 |
| 2024-05-13 | P1/P2 | Bristol-Myers Squibb BMY | NCT06024174 A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tu | Advanced Solid Tumors | terminated | 5 |
| 2024-05-14 | P2 | Beijing Pearl Biotechnology Limited Liability Company | NCT04258033 A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) | Non-small Cell Lung Cancer | completed | 145 |
| 2024-05-14 | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT04417972 The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis. | Endometriosis | completed | 179 |
| 2024-05-14 | P2 | Janssen Research & Development, LLC | NCT05071664 A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | Arthritis, Psoriatic | completed | 91 |
| 2024-05-14 | P2 | Provention Bio, a Sanofi Company | NCT05087628 PRV-3279-2a Trial in Systemic Lupus | Systemic Lupus Erythematosus | terminated | 28 |
| 2024-05-14 | P3 | JW Pharmaceutical | NCT05814393 To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | completed | 200 |
| 2024-05-15 | P3 | Pfizer PFE | NCT04281485 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | active not recruiting | 114 |
| 2024-05-15 | P2 | Hoffmann-La Roche | NCT04299464 A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Diso | Autism Spectrum Disorder (ASD) | completed | 104 |
| 2024-05-15 | P3 | Bayer | NCT04435626 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportio | Heart Failure | completed | 6016 |
| 2024-05-15 | P1/P2 | Compugen Ltd CGEN | NCT04570839 COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Endometrial Neoplasms; Ovarian Cancer; Solid Tumor; Head and Neck Cancer | completed | 48 |
| 2024-05-15 | P2 | CalciMedica, Inc. CALC | NCT04681066 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS | Acute Pancreatitis; Systemic Inflammatory Response Syndrome | completed | 216 |
| 2024-05-15 | P3 | AKARI Therapeutics AKTX | NCT04784455 Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Thrombotic Microangiopathies | terminated | 10 |
| 2024-05-15 | P2 | ILiAD Biotechnologies | NCT05116241 Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children | Bordetella Pertussis, Whooping Cough | completed | 368 |
| 2024-05-15 | P3 | Eli Lilly and Company LLY | NCT05275400 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin | Type 2 Diabetes | completed | 986 |
| 2024-05-15 | P2 | Ascletis Pharmaceuticals Co., Ltd. | NCT05330143 Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV | HIV-1-infection; HIV Infections; PD-L1 Gene Mutation | completed | 19 |
| 2024-05-15 | P3 | Shanghai Henlius Biotech | NCT05346224 A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced | Breast Cancer; Breast Neoplasms; HER2-positive Breast Cancer | active not recruiting | 900 |
| 2024-05-15 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05762458 The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | Major Depressive Disorder (MDD) | unknown | 240 |
| 2024-05-15 | P2 | VivaVision Biotech, Inc | NCT06164743 Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery | Inflammation | completed | 91 |
| 2024-05-16 | P3 | SetPoint Medical Corporation | NCT04539964 Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | active not recruiting | 243 |
| 2024-05-16 | P2 | NS Pharma, Inc. | NCT04854096 Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofib | terminated | 7 |
| 2024-05-16 | P2 | Eli Lilly and Company LLY | NCT05616013 Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity; Obese; Overweight or Obesity | completed | 507 |
| 2024-05-16 | P3 | Eli Lilly and Company LLY | NCT05738486 A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) | Alzheimer's Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Disea | active not recruiting | 1175 |
| 2024-05-16 | P3 | Cellular Sciences, inc. | NCT06037408 The Effect of N115 on Coughing in IPF Patients | Idiopathic Pulmonary Fibrosis | completed | 50 |
| 2024-05-16 | P3 | Biocad | NCT06987851 An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC | Multiple Sclerosis | completed | 44 |
| 2024-05-17 | P1/P2 | MedPacto, Inc. | NCT03732274 Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC | Non-Small Cell Lung Cancer Metastatic | completed | 60 |
| 2024-05-17 | P2 | Janssen Pharmaceutica N.V., Belgium | NCT05328297 A Study of JNJ-55308942 in the Treatment of Bipolar Depression | Bipolar Disorder | completed | 116 |
| 2024-05-17 | P3 | Incyte Corporation INCY | NCT05456529 Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 103 |
| 2024-05-17 | P2 | Novartis Pharmaceuticals NVS | NCT05670106 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCR | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | 62 |
| 2024-05-17 | P3 | Johnson & Johnson Consumer Inc. (J&JCI) JNJ | NCT05761574 A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain | Pain | completed | 447 |
| 2024-05-17 | P2 | AstraZeneca AZN | NCT06057064 Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response A | COVID-19, SARS-CoV-2 | completed | 116 |
| 2024-05-18 | P2 | InventisBio Co., Ltd | NCT05504083 Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients | Hyperuricemia | completed | 121 |
| 2024-05-20 | P3 | pharmaand GmbH | NCT03522246 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage II | active not recruiting | 1097 |
| 2024-05-20 | P3 | AbbVie ABBV | NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipat | Functional Constipation; Irritable Bowel Syndrome With Constipation | completed | 438 |
| 2024-05-20 | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT04950322 A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | Gastric or Gastroesophageal Junction Cancer | active not recruiting | 737 |
| 2024-05-20 | P2 | Osteal Therapeutics, Inc. | NCT05607030 A Second Trial of the Abbreviated Protocol Two-Stage Exchange | Prosthetic-joint Infection | completed | 76 |
| 2024-05-20 | P2 | Levicept | NCT05618782 Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee | Pain; Osteo Arthritis Knee; Knee Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases | completed | 518 |
| 2024-05-20 | P2 | Caliway Biopharmaceuticals Co., Ltd. | NCT05736107 A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat | Subcutaneous Fat | completed | 107 |
| 2024-05-21 | P1/P2 | Genentech, Inc. | NCT02500407 A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and C | Lymphocytic Leukemia, Chronic; Lymphoma, Non Hodgkin | completed | 713 |
| 2024-05-21 | P3 | Grifols Therapeutics LLC GRFS | NCT03451292 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites | Decompensated Cirrhosis and Ascites | completed | 410 |
| 2024-05-21 | P2 | AbbVie ABBV | NCT04244175 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | Seizures | completed | 154 |
| 2024-05-21 | P2/P3 | Novavax NVAX | NCT05925127 Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | COVID-19 | completed | 994 |
| 2024-05-21 | P2 | Intuitive Surgical ISRG | NCT05946603 IS-002 Phase 2 Prostate Cancer Study | Prostate Cancer | completed | 59 |
| 2024-05-21 | P1/P2 | GlaxoSmithKline | NCT05975840 Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medical | Influenza, Human | completed | 518 |
| 2024-05-21 | P3 | Click Therapeutics, Inc. CLIK | NCT06004388 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) | Migraine; Episodic Migraine; Headache; Headache, Migraine | completed | 110 |
| 2024-05-21 | P2 | Telios Pharma, Inc. | NCT06293820 A Study Of TL-925 For The Treatment of AC | Allergic Conjunctivitis | completed | 80 |
| 2024-05-21 | P3 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | NCT07563634 Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy | Epilepsy, Focal | completed | 141 |
| 2024-05-22 | P1/P2 | Bristol-Myers Squibb BMY | NCT01968109 An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid | Neoplasms by Site | completed | 1482 |
| 2024-05-22 est. | P2/P3 | EmeraMed | NCT04183595 NBMI Treatment in Patients With Mercury Toxicity | Mercury Poisoning | unknown | 116 |
| 2024-05-22 | P3 | UCB Biopharma SRL | NCT04294667 A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 321 |
| 2024-05-22 | P2 | Janssen Research & Development, LLC | NCT04633447 A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis | Giant Cell Arteritis | terminated | 53 |
| 2024-05-22 | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05102006 A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors | Advanced Malignant Tumors | completed | 80 |
| 2024-05-22 | P2 | Contera Pharma A/S | NCT05516875 Open-Label Extension Study of ASTORIA | Dyskinesias | terminated | 6 |
| 2024-05-22 | P1/P2 | Teva Branded Pharmaceutical Products R&D LLC | NCT05590377 A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | terminated | 15 |
| 2024-05-22 | P2/P3 | Nektar Therapeutics NKTR | NCT05664217 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Non-Hodgkin Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | 15 |
| 2024-05-22 est. | P1/P2 | Shandong New Time Pharmaceutical Co., LTD | NCT05740215 Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | Solid Tumors | unknown | 158 |
| 2024-05-22 | P2 | Ocular Therapeutix, Inc. OCUL | NCT05814757 OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | Dry Eye Syndromes; Eye Diseases | completed | 100 |
| 2024-05-22 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovaria | terminated | 7 |
| 2024-05-22 | P3 | Taejoon Pharmaceutical Co., Ltd. | NCT06427031 Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients | Dry Eye; Dry Eye Syndromes | completed | 271 |
| 2024-05-23 | P1/P2 | Translational Biosciences TDAC | NCT02192736 Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma | Asthma | terminated | 20 |
| 2024-05-23 | P3 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | NCT03355209 A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrom | Lennox Gastaut Syndrome | completed | 296 |
| 2024-05-23 | P2 | Sanofi SNY | NCT05002777 Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) | Warm Autoimmune Hemolytic Anemia (wAIHA) | active not recruiting | 22 |
| 2024-05-23 | P2 | Albimmune SL | NCT05645887 Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure. | Septic Shock | withdrawn | |
| 2024-05-23 | P3 | Sinovac Biotech Co., Ltd SVA | NCT06049927 A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months | Seasonal Influenza | completed | 3300 |
| 2024-05-24 | P3 | AstraZeneca AZN | NCT03927157 Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma | Asthma | completed | 405 |
| 2024-05-24 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04796623 A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer | HR-positive, HER2-negative Advanced Breast Cancer | completed | 122 |
| 2024-05-24 | P3 | G1 Therapeutics, Inc. | NCT04799249 Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) | TNBC - Triple-Negative Breast Cancer; Breast Cancer | completed | 194 |
| 2024-05-24 | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT04820309 An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) | Schizophrenia | completed | 566 |
| 2024-05-24 | P2 | UCB Biopharma SRL | NCT04867616 A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) | Alzheimer's Disease | completed | 466 |
| 2024-05-24 | P1/P2 | Eisai Inc. | NCT04971733 A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disea | Alzheimer Disease | completed | 8 |
| 2024-05-24 | P2/P3 | ALX Oncology Inc. ALXO | NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma | completed | 127 |
| 2024-05-24 | P1/P2 | Wave Life Sciences USA, Inc. WVE | NCT05032196 Study of WVE-003 in Patients With Huntington's Disease | Huntington Disease | completed | 47 |
| 2024-05-24 | P2 | Rivus Pharmaceuticals, Inc. | NCT05284617 Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF | Heart Failure With Preserved Ejection Fraction | completed | 67 |
| 2024-05-24 | P3 | Bio-Thera Solutions | NCT05377944 Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients | Plaque Psoriasis | completed | 502 |
| 2024-05-24 | P2 | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | NCT05399368 An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis | Atopic Dermatitis | terminated | 229 |
| 2024-05-24 | P1/P2 | Genmab GMAB | NCT05435339 A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | Solid Tumor, Adult | terminated | 31 |
| 2024-05-24 est. | P3 | Qilu Pharmaceutical (Hainan) Co., Ltd. | NCT05922436 a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency | Hypertensive Emergency | unknown | 378 |
| 2024-05-24 | P2 | Inventprise Inc. | NCT06077656 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine | Pneumococcal Vaccines | completed | 220 |
| 2024-05-24 | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07278830 A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia | Hypercholesterolemia and Mixed Dyslipidemia | completed | 214 |
| 2024-05-25 | P3 | Takeda TAK | NCT03999996 Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose | Dengue Fever | completed | 365 |
| 2024-05-25 est. | P2/P3 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | NCT05661240 Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields (EFE-P100)Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Diseas | Non-small Cell Lung Cancer (NSCLC) | unknown | 348 |
| 2024-05-25 | P3 | Johnson & Johnson Consumer Inc. (J&JCI) JNJ | NCT05868122 A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy | Pain | completed | 143 |
| 2024-05-26 | P2 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | NCT06800157 Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis | Arthritis, Rheumatoid | completed | 72 |
| 2024-05-27 | P3 | Gilead Sciences GILD | NCT04994509 Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 5368 |
| 2024-05-27 | P3 | Swedish Orphan Biovitrum | NCT05096403 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) | Cold Agglutinin Disease | completed | 24 |
| 2024-05-27 | P2 | Pierre Fabre Medicament | NCT05195632 Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 63 |
| 2024-05-27 | P2 | Celon Pharma SA | NCT05374785 Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 106 |
| 2024-05-27 | P2 | Regeneron Pharmaceuticals REGN | NCT05618808 A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants | Venous Thromboembolism | completed | 373 |
| 2024-05-27 est. | P1/P2 | Guangdong Ruishun Biotech Co., Ltd | NCT05858814 RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | Acute Myeloid Leukemia | unknown | 72 |
| 2024-05-27 | P2 | Pfizer PFE | NCT06116591 A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers | Healthy Participants | completed | 105 |
| 2024-05-27 | P3 | GlaxoSmithKline | NCT06956170 All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | active not recruiting | 21 |
| 2024-05-28 | P2 | Bristol-Myers Squibb BMY | NCT02927769 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Trea | Hodgkin Disease | completed | 72 |
| 2024-05-28 | P1/P2 | BioNTech SE BNTX | NCT04455620 BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | Solid Tumor | terminated | 49 |
| 2024-05-28 | P3 | Amgen AMGN | NCT04524273 Myasthenia Gravis Inebilizumab Trial | Myasthenia Gravis | active not recruiting | 238 |
| 2024-05-28 | P3 | Hoffmann-La Roche | NCT04660539 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica Spectrum Disorder | completed | 119 |
| 2024-05-28 | P3 | Arcutis Biotherapeutics, Inc. ARQT | NCT04804605 Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Atopic Dermatitis Eczema | completed | 1220 |
| 2024-05-28 | P3 | Eurofarma Laboratorios S.A. | NCT04972292 Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction | Pain | completed | 288 |
| 2024-05-28 | P3 | Eurofarma Laboratorios S.A. | NCT05081102 Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction | Pain | completed | 288 |
| 2024-05-28 | P3 | Sedana Medical | NCT05327296 Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive C | Sedation | completed | 282 |
| 2024-05-28 | P3 | NewAmsterdam Pharma NAMS | NCT05425745 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | Dyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Lipid Metaboli | completed | 354 |
| 2024-05-28 | P2 | UCB Biopharma SRL | NCT05643794 A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome | Fibromyalgia | completed | 63 |
| 2024-05-28 | P2 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | NCT05689047 Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) | Acute Malaria | completed | 38 |
| 2024-05-28 est. | P1/P2 | 1Globe Biomedical Co., Ltd. | NCT05784779 Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD | NASH; NAFLD | unknown | 180 |
| 2024-05-28 | P3 | GlaxoSmithKline | NCT06025695 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in | Gastroenteritis | completed | 2000 |
| 2024-05-28 | P3 | ModernaTX, Inc. | NCT06097273 A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age | SARS-CoV-2; Influenza | completed | 8061 |
| 2024-05-28 | P3 | Qilu Pharmaceutical (Hainan) Co., Ltd. | NCT06932107 Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting | Postoperative Nausea and Vomiting | completed | 518 |
| 2024-05-29 | P2 | Cognition Therapeutics CGTX | NCT03507790 A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. | Mild to Moderate Alzheimer's Disease | completed | 153 |
| 2024-05-29 | P3 | Alzheon Inc. | NCT04770220 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | Early Alzheimer's Disease | completed | 325 |
| 2024-05-29 | P2 | Unicycive Therapeutics, Inc UNCY | NCT06218290 A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis | Chronic Kidney Disease Requiring Chronic Dialysis | completed | 106 |
| 2024-05-30 | P2 | Theravia | NCT03806452 SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) | Sickle Cell Disease | completed | 86 |
| 2024-05-30 est. | P2 | Shanghai Henlius Biotech | NCT03941574 A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy | MSI-H Solid Malignant Tumor | unknown | 108 |
| 2024-05-30 est. | P2 | Shanghai Henlius Biotech | NCT04297995 Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors | Head and Neck Squamous Cell Carcinoma | unknown | 131 |
| 2024-05-30 | P2 | MGC Pharmaceuticals d.o.o | NCT04406948 Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies | Resistant Epilepsy, Drug; Adolescent Epilepsy; Children Epilepsy; Children and Adolescents With Resi | withdrawn | |
| 2024-05-30 est. | P2 | Nature Cell Co. Ltd. | NCT04482413 Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease | Alzheimer Disease | unknown | 100 |
| 2024-05-30 est. | P2 | Tianjin Chasesun Pharmaceutical Co., LTD | NCT04803955 Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients | Sepsis | unknown | 424 |
| 2024-05-30 | P3 | LIB Therapeutics LLC | NCT05004675 Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients | Hypercholesterolemia; Atherosclerotic Ischemic Disease | completed | 166 |
| 2024-05-30 | P2 | Jazz Pharmaceuticals JAZZ | NCT05122650 A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) | Essential Tremor | completed | 420 |
| 2024-05-30 est. | P1/P2 | Galecto Biotech AB | NCT05240131 A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer ( | Non-Small Cell Lung Cancer | unknown | 88 |
| 2024-05-30 est. | P3 | Glenmark Pharmaceuticals Ltd. India | NCT05363202 To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma | Bronchial Asthma | unknown | 790 |
| 2024-05-30 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT05396339 A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | Advanced Malignant Solid Tumor | unknown | 120 |
| 2024-05-30 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT05396391 A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | Advanced Malignant Tumors | unknown | 140 |
| 2024-05-30 est. | P1/P2 | ZEO ScientifiX, Inc. ZEOX | NCT05643729 Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD) | COPD | suspended | 20 |
| 2024-05-30 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05797623 Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia | Non-severe Aplastic Anemia | unknown | 78 |
| 2024-05-30 | P3 | Bayer | NCT05915702 A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal | Contrast Enhancement in Magnetic Resonance Imaging; Central Nervous System Pathology | completed | 321 |
| 2024-05-30 | P2 | Boehringer Ingelheim | NCT06082843 A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleedin | Hypertension, Portal; Liver Cirrhosis | terminated | 22 |
| 2024-05-30 est. | P2 | Chengdu CoenBiotech Co., Ltd | NCT06305104 Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old | Tuberculosis | unknown | 420 |
| 2024-05-31 | P2 | Merck Sharp & Dohme LLC MRK | NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metas | Squamous Cell Carcinoma of Head and Neck | terminated | 408 |
| 2024-05-31 | P3 | Lupin Ltd. | NCT04690556 Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD | Neovascular Age-related Macular Degeneration | completed | 600 |
| 2024-05-31 | P2 | Calliditas Therapeutics Suisse SA | NCT05014672 A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness | Primary Biliary Cholangitis; Liver Stiffness | completed | 76 |
| 2024-05-31 est. | P2 | DermBiont, Inc. | NCT05136144 Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis | Seborrheic Keratosis | unknown | 70 |
| 2024-05-31 | P2 | Aston Sci. Inc. | NCT05163223 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | Breast Cancer | terminated | 10 |
| 2024-05-31 est. | P3 | Nihon Pharmaceutical Co., Ltd | NCT05177939 Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis | Autoimmune Encephalitis | unknown | 40 |
| 2024-05-31 | P3 | Daiichi Sankyo | NCT05338970 HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI The | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R; EGFR Exon 19 Deletion | active not recruiting | 586 |
| 2024-05-31 | P1/P2 | Akeso | NCT05559541 Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | terminated | 33 |
| 2024-05-31 | P2 | ImaginAb, Inc. | NCT05744128 CD8 Minibody Repeatability Study | Melanoma; Renal Cell Carcinoma | terminated | 3 |
| 2024-05-31 est. | P3 | NVP Healthcare | NCT05856487 To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients | Cardiovascular Diseases | unknown | 228 |
| 2024-05-31 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05865496 A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Sinusitis; Nasal Polyps; Polyps | unknown | 90 |
| 2024-05-31 | P1/P2 | Thryv Therapeutics THRY | NCT05906732 Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrom | Long QT Syndrome | terminated | 42 |
| 2024-05-31 | P3 | Bayer | NCT05915728 A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of | Contrast Enhancement in Magnetic Resonance Imaging; Non-central Nervous System Pathology | completed | 410 |
| 2024-05-31 | P3 | Regeneron Pharmaceuticals REGN | NCT05989126 Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (nAMD) | completed | 35 |
| 2024-05-31 est. | P3 | Suzhou Kintor Pharmaceutical Inc, | NCT06126965 Phase III Study of KX-826 With Adult Male Patients With AGA | Androgenetic Alopecia | unknown | 740 |
| 2024-05-31 est. | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06133166 A Study for the Treatment of Dry Eye in Postmenopausal Women | Postmenopausal Women With DED | unknown | 240 |
| 2024-05-31 | P2 | Soligenix SNGX | NCT06149247 HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | completed | 10 |
| 2024-05-31 | P2 | LianBio LLC | NCT06206278 Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | terminated | 6 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.